Claims
- 1. A method for treating multiple myeloma in a subject comprising administering irinotecan in combination with revimid.
- 2. The method of claim 1, wherein the irinotecan is a pharmaceutically acceptable salt.
- 3. The method of claim 2, wherein the pharmaceutically acceptable salt of irinotecan is a hydrochloride salt.
- 4. The method of claim 3, wherein the irinotecan hydrochloride salt is CPT-11.
- 5. The method of claim 1, wherein the irinotecan is administered as an oral dosage form.
- 6. The method of claim 1, wherein the revimid is administered as an oral dosage form.
- 7. The method of claim 1, wherein the irinotecan and revimid are administered sequentially.
- 8. The method of claim 7, where the irinotecan and revimid are administered sequentially in any order.
- 9. The method of claim 1, wherein the irinotecan and revimid are administered simultaneously.
- 10. The method of claim 1, wherein the subject has had prior chemotherapy.
- 11. The method of claim 10 wherein the prior chemotherapy comprises treatment with MP, treatment with VAD, or treatment with one or more alkylating agents.
- 12. The method of claim 10 wherein the prior chemotherapy comprises treatment with cyclophosphamide and etoposide, or treatment with etoposide, dexamethasone and doxorubicin.
- 13. The method of claim 10 wherein irinotecan and revimid are administered sequentially, in any order.
- 14. The method of claim 10 wherein irinotecan and revimid are administered simultaneously.
- 15. A pharmaceutical preparation for the treatment of multiple myeloma comprising irinotecan and revimid.
- 16. The pharmaceutical preparation of claim 15 wherein the irinotecan and the revimid are provided in a single dosage device.
- 17. The pharmaceutical preparation of claim 15 wherein the irinotecan and the revimid are provided in separate dosage devices.
- 18. A method for treating multiple myeloma in a patient comprising administering oral irinotecan in combination with oral revimid.
- 19. The method of claim 18, wherein the irinotecan is a pharmaceutically acceptable salt form.
- 20. The method of claim 19, wherein the pharmaceutically acceptable salt form of irinotecan is a hydrochloride salt.
- 21. The method of claim 20, wherein the irinotecan hydrochloride salt is CPT-11.
- 22. The method of claim 18, wherein the irinotecan and revimid are administered sequentially.
- 23. The method of claim 22, where the irinotecan and revimid are administered sequentially in any order.
- 24. The method of claim 18, wherein the irinotecan and revimid are administered simultaneously.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. Provisional Patent Application Ser. No. 60/471,601, filed May 19, 2003.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60471601 |
May 2003 |
US |